- Title: Subtitle
- Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study
- Creators
- Tanya Jindal - University of California, San FranciscoCindy Y Jiang - The University of Texas MD Anderson Cancer CenterOmar Alhalabi - The University of Texas MD Anderson Cancer CenterCharles B Nguyen - University of MichiganEugene Oh - Michigan Center for Translational PathologyIrene Tsung - Michigan Center for Translational PathologyDimitra Rafailia Bakaloudi - University of WashingtonRafee Talukder - University of WashingtonMatthew Davidsohn - Dana-Farber Cancer InstituteDory Freeman - Dana-Farber Cancer InstituteIlana Y Epstein - Dana-Farber Cancer InstituteChien-Kuang Cornelia Ding - University of California, San FranciscoAmanda Nizam - Cleveland ClinicMichael J Glover - Stanford UniversityAli Raza Khaki - Stanford UniversityAmy K Taylor - University of Wisconsin Carbone Cancer CenterEmily Lemke - Medical College of WisconsinAlbert Jang - University Hospitals Seidman Cancer CenterSean T Evans - Emory UniversityDenny Shin - Winship Cancer InstituteCameron Pywell - University of Alabama at BirminghamArnab Basu - University of Alabama at BirminghamMehmet A Bilen - Emory UniversityYousef Zakharia - University of IowaPedro Barata - Tulane UniversityMatthew I Milowsky - University of North Carolina at Chapel HillJason Brown - University Hospitals Seidman Cancer CenterDeepak Kilari - Medical College of WisconsinHamid Emamekhoo - University of Wisconsin–MadisonChristopher J Hoimes - Duke UniversitySumit Shah - Stanford UniversityNancy B Davis - Vanderbilt UniversityShilpa Gupta - Cleveland ClinicPetros Grivas - University of WashingtonJoaquim Bellmunt - Dana-Farber Cancer InstituteAjjai Alva - Michigan Center for Translational PathologyMatthew T Campbell - The University of Texas MD Anderson Cancer CenterVadim S Koshkin - University of California, San Francisco
- Resource Type
- Letter/Communication
- Publication Details
- European urology, Vol.90(1), pp.85-87
- DOI
- 10.1016/j.eururo.2025.09.003
- PMID
- 40954009
- NLM abbreviation
- Eur Urol
- ISSN
- 1873-7560
- eISSN
- 1873-7560
- Publisher
- Elsevier
- Language
- English
- Electronic publication date
- 09/14/2025
- Date published
- 07/2026
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984963154702771
Letter/Communication
Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study
European urology, Vol.90(1), pp.85-87
07/2026
DOI: 10.1016/j.eururo.2025.09.003
PMID: 40954009
Details
Metrics
5 Record Views